.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
QuintilesIMS
McKesson
Novartis
Johnson and Johnson
Teva
Covington
AstraZeneca
Argus Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

Hoffmann-la Roche Company Profile

« Back to Dashboard

What is the competitive landscape for HOFFMANN-LA ROCHE, and when can generic versions of HOFFMANN-LA ROCHE drugs launch?

HOFFMANN-LA ROCHE has two approved drugs.

There are three US patents protecting HOFFMANN-LA ROCHE drugs.

There are sixty-one patent family members on HOFFMANN-LA ROCHE drugs in thirty-six countries and nine supplementary protection certificates in six countries.

Summary for Hoffmann-la Roche

International Patents:61
US Patents:3
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann-la Roche
INVIRASE
saquinavir mesylate
TABLET;ORAL021785-001Dec 17, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hoffmann-la Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann-la Roche
INVIRASE
saquinavir mesylate
TABLET;ORAL021785-001Dec 17, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hoffmann-la Roche Drugs

Country Document Number Estimated Expiration
Japan5628603► Subscribe
Taiwan201103537► Subscribe
New Zealand597477► Subscribe
New Zealand608312► Subscribe
Japan4918630► Subscribe
Canada2764653► Subscribe
European Patent Office2606886► Subscribe
Serbia20110548► Subscribe
European Patent Office2441753► Subscribe
TaiwanI526441► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hoffmann-la Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017017Lithuania► SubscribePRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
C0048Belgium► SubscribePRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
2017000048Germany► SubscribePRODUCT NAME: ALECTINIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/16/1169 20170216
0876Netherlands► SubscribePRODUCT NAME: ALECTINIB DAN WEL EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1169/001 20170220
70013Netherlands► SubscribePRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
/1996Austria► SubscribePRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
2017 00024Denmark► SubscribePRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/16/1169/01 20170220
C0044Belgium► SubscribePRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
2017 00024Denmark► SubscribePRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF, HERUNDER I FORM AF HYDROCHLORID; REG. NO/DATE: EU/1/16/1169/01 20170220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Citi
Covington
Federal Trade Commission
Argus Health
UBS
Moodys
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot